Athenex
Athenex is focused on the development and commercialization of therapies for cancer and immunomodulatory diseases.
Launch date
Employees
Market cap
€135m
Enterprise valuation
€237m (Public information from Aug 2023)
Share price
$0.0152 ATNX
Buffalo New York (HQ)
Financials
Estimates*
USD | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|---|
Revenues | - | 38.0m | 89.1m | 101m | 144m | 120m | 103m |
% growth | - | - | 134 % | 13 % | 43 % | (17 %) | (14 %) |
EBITDA | - | (106m) | (123m) | (116m) | (119m) | (110m) | (71.8m) |
% EBITDA margin | - | (279 %) | (138 %) | (115 %) | (83 %) | (92 %) | (70 %) |
Profit | - | (131m) | (117m) | (124m) | (146m) | (200m) | (103m) |
% profit margin | - | (345 %) | (131 %) | (123 %) | (101 %) | (167 %) | (100 %) |
EV / revenue | - | 23.0x | 8.8x | 10.7x | 6.8x | 2.2x | 1.2x |
EV / EBITDA | - | -8.2x | -6.4x | -9.3x | -8.3x | -2.4x | -1.7x |
R&D budget | 63.8m | 69.3m | 114m | 82.5m | - | - | - |
R&D % of revenue | - | 182 % | 128 % | 82 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $5.0m | - | |
N/A | $300k | - | |
* | N/A | $40.0m | Private Placement VC |
* | N/A | $48.1m | Growth Equity VC |
N/A | $66.0m Valuation: $607m | IPO | |
$50.0m | Post IPO Equity | ||
* | $100m | Post IPO Equity | |
$60.0m | Post IPO Equity | ||
* | N/A | $30.0m | Post IPO Equity |
N/A | N/A | Bankruptcy | |
Total Funding | €109m |
Recent News about Athenex
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Athenex
EditACQUISITION by Athenex Sep 2014
ACQUISITION by Athenex Dec 2015
ACQUISITION by Athenex May 2021